Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Search content at Experts@Minnesota
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
Tiotropium - Advancing the treatment of COPD
Scott Chambers
, Michael Schachter
, David Price
, George Kassianos
, Allan Gaw
, Michael Kirby
, Jonathan Morrell
, Juan Tamargo
, Barbara Yawn
, Roy Yawn
, Khalid Barakat
, Pam Brown
, Jamie Dalrymple
, Kurt Elward
, Ted Ganiats
, David Halpin
, Mike LeFevre
, Frederick North
, Jill Rasmussen
, Steven Spann
Richard Stevens, Alfred F. Tallia, Don Uden, Marion Waite, Derek Waller
Show 5 others
Show less
Pharmaceutical Care and Health Systems
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Tiotropium - Advancing the treatment of COPD'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Chronic Obstructive Pulmonary Disease
100%
Treatment of Chronic Obstructive Pulmonary Disease
100%
Bronchodilating Agent
80%
Parasympatholytic
60%
Dyspnea
40%
Endurance Training
40%
Clinical Trial
20%
Lung
20%
Combination Therapy
20%
Rehabilitation Engineering
20%
Health Status
20%
Adverse Event
20%
Mucus
20%
Xerostomia
20%
Pulmonary Rehabilitation
20%
Muscarinic Acetylcholine Receptor
20%
Post-Hoc Analysis
20%
Inspiratory Capacity
20%
Fluticasone Propionate
20%
Bronchoconstriction
20%
Salmeterol
20%
Formoterol
20%
Keyphrases
Chronic Obstructive Pulmonary Disease
100%
Tiotropium
100%
Anticholinergic Bronchodilators
25%
Inhaled Anticholinergics
16%
Exercise Endurance
16%
Clinical Trials
8%
Combination Therapy
8%
Safety Assessment
8%
Treatment Choice
8%
Health Status
8%
Acute Exacerbation
8%
Safety Profile
8%
Hospitalization
8%
Patient-centered Outcomes
8%
During Exercise
8%
Muscarinic Receptors
8%
Inspiratory Capacity
8%
Additive Effect
8%
Adverse Events
8%
Decline Rate
8%
Dyspnea
8%
Breathlessness
8%
Clinical Improvement
8%
Bronchoconstriction
8%
Mucus Hypersecretion
8%
Pulmonary Rehabilitation
8%
Stable Chronic Obstructive Pulmonary Disease
8%
Degree of Severity
8%
Ipratropium
8%
Endurance Time
8%
Triple Combination
8%
Airway Function
8%
Bronchodilator
8%
Dry Mouth
8%
Treatment Discontinuation
8%
Decline in Lung Function
8%
Fluticasone Propionate
8%
Long-acting β2-agonist
8%
Short-acting Anticholinergics
8%
Function Characteristic
8%
Salmeterol
8%
Formoterol
8%
Airway Volume
8%
Current Recommendations
8%
Biochemistry, Genetics and Molecular Biology
Endurance Training
100%
Clinical Trial
50%
Agonist
50%
Health Status
50%
Formoterol
50%
Salmeterol
50%
Inspiratory Capacity
50%
Muscarinic Acetylcholine Receptor
50%
Fluticasone Propionate
50%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Obstructive Lung Disease
100%
Bronchodilating Agent
66%
Cholinergic Receptor Blocking Agent
50%
Dyspnea
33%
Clinical Trial
16%
Health Status
16%
Muscarinic Receptor
16%
Adverse Event
16%
Fluticasone Propionate
16%
Combination Therapy
16%
Xerostomia
16%
Bronchoconstriction
16%
Formoterol
16%
Salmeterol
16%